A Phase 2 interventional study of Aripiprazole and Olanzapine in Schizophrenia and Schizoaffective Disorder, sponsored by Janssen Research & Development, LLC. Terminated at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 121st largest by enrollment of the 125 interventional ones that give a count, is one of 5 that started in 2015, is one of 4 in phase 2, and was the 92nd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 169th largest by enrollment of the 176 interventional ones that give a count, is one of 6 that started in 2015, is one of 11 in phase 2, and was the 186th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit when antipsychotic medication plasma levels (AMPL) results are available compared to when AMPL results are not available.
This is a naturalistic, open-label (all people know the identity of the intervention), multicenter (when more than one hospital or medical school team work on a medical research study), pilot clinical utility study with a sequential and parallel cohort design in participants with a diagnosis of schizophrenia or schizoaffective disorder. The study consists of up to 3 Phases: Screening Phase (Screening and first assessment visit should preferably take place on the same day), active assessment phase (12 weeks, An optional 12 week extension phase. Participants will be assigned to Cohort 1, or randomized to Cohort 2 or Cohort 3. Participants in cohorts 2 and 3 who are receiving long acting injectable (LAI) formulations of paliperidone and/or risperidone and complete participation in the active assessment phase) will have the option of continuing into the extension phase. The duration of study participation will be approximately 12 weeks. Participants in the optional extension phase will have an additional 12 weeks of study participation. The primary outcome will be measured by the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.
Drug: Aripiprazole · Drug: Olanzapine · Drug: Paliperidone · Drug: Quetiapine · Drug: Risperidone
Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.
Drug: Aripiprazole · Drug: Olanzapine · Drug: Paliperidone · Drug: Quetiapine · Drug: Risperidone
Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.
Drug: Aripiprazole · Drug: Olanzapine · Drug: Paliperidone · Drug: Quetiapine · Drug: Risperidone
Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
Number of Participants With Medication Treatment Modifications (MTM)
Information on MTMs derived from data collected in the clinical assessment of the schizophrenia patient (CASP) questionnaire. The CASP captured changes in medications, changes in psychosocial treatments, visit frequency, and the need for any acute interventions. The CASP comprised of 3 sections covering several parameters. The CASP captured changes in treatment options which was used to compute MTM, as well as factors in clinical decision making and the influence of antipsychotic medication plasma levels (AMPL), when they were available, on clinical decision making.
Time frame: Up to Week 12
Clinical Global Impression-Severity (CGI-S) Score at Week 0 and 12
Clinical Global Impression-Severity (CGI-S) rating scale used to rate the severity of a participant's overall clinical condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe). Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time frame: Week 0, Week 12
Dimensions of Psychosis Symptom Severity Scale (DPSS) Total Score at Week 0 and 12
The DPSS is a clinician-rated scale used to rate 8 domains commonly seen in patients with psychotic disorders. Each domain was rated on a 5-point scale (0 to 4) with anchored description of endpoints. Total score was computed by summing the scores of individual items (range of 0-32). Higher scores represent more severe condition. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time frame: Week 0, Week 12
Antipsychotic Medication Plasma Levels (AMPL) During the Active Assessment Phase at Week 12
AMPL of the individual participant during the active assessment phase was reported.
Time frame: Week 12
Number of Participants With Factors Considered in Clinical Decision as Assessed by Clinical Assessment of the Schizophrenia Patient (CASP)
The CASP and data on concomitant medications and psychosocial treatments were used to evaluate the impact of AMPL results on other aspects of clinical decision making.
Time frame: Up to Week 12
Clinician's Rating Scale of Adherence (CRS) Score at Week 0 and 12
The CRS is an ordinal scale filled by the clinician. The scores range from 1 to 7 that were used to quantify the clinician's assessment of treatment adherence by the patient. Higher scores indicate greater adherence. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time frame: Week 0, Week 12
Adherence to Antipsychotic Medication as Assessed by Brief Adherence Rating Scale (BARS) at Week 0 and 12
The BARS is a 4-item scale that includes 3 questions and an overall visual analog rating scale that assesses participant's knowledge about his/her medication. The key measure of adherence is the visual analog scale and assesses the percentage of doses taken by the participants in the past month (0 percent \[%\] - 100%). The 3 questions include: number of prescribed doses per day, number of days in the past month when the participant did not take the prescribed doses, and the number of days in the past month when the participant took less than the prescribed dose. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time frame: Week 0, Week 12
Patient Satisfaction Survey (PSS) Total Score at Week 0 and 12
The PSS is a brief scale designed to capture a psychiatric patient's satisfaction with a clinician. The scale covers 6 domains: Trust (3 items), Communication (3 items), Exploration of Ideas/Options (2 items), Body Language (2 items), Active Listening (4 items), and Miscellaneous Items (6 items). Out of the 20 items, the first 19 are scored on a 5-point Likert Scale (1=strongly disagree, 2=disagree, 3=satisfactory, 4=agree, 5=strongly agree). The last question (6f) is a free-response question asking for input on how the clinician might improve. Sum of scores of individual items give a total score (range 9-95). Higher scores indicate greater degree of satisfaction. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time frame: Week 0, Week 12
| Milestone | Cohort 1 |
|---|---|
| Started | 9 |
| Completed | 5 |
| Not completed | 4 |
| Withdrew: Death | 1 |
| Withdrew: Other | 3 |
Information on MTMs derived from data collected in the clinical assessment of the schizophrenia patient (CASP) questionnaire. The CASP captured changes in medications, changes in psychosocial treatments, visit frequency, and the need for any acute interventions. The CASP comprised of 3 sections covering several parameters. The CASP captured changes in treatment options which was used to compute MTM, as well as factors in clinical decision making and the influence of antipsychotic medication plasma levels (AMPL), when they were available, on clinical decision making.
| Participants | Cohort 1 |
|---|---|
| Number of Participants With Medication Treatment Modifications (MTM) | 4 |
Clinical Global Impression-Severity (CGI-S) rating scale used to rate the severity of a participant's overall clinical condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe). Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
| units on a scale | Cohort 1 |
|---|---|
| Participant 1 (Week 0) | 4 |
| Participant 1 (Week 12) | 3 |
| Participant 2 (Week 0) | 4 |
| Participant 2 (Week 12) | 3 |
| Participant 3 (Week 0) | 4 |
| Participant 3 (Week 12) | 4 |
| Participant 4 (Week 0) | 5 |
| Participant 5 (Week 0) | 3 |
| Participant 5 (Week 12) | 3 |
| Participant 6 (Week 0) | 3 |
| Participant 6 (Week 12) | 3 |
| Participant 7 (Week 0) | 3 |
| Participant 7 (Week 12) | 4 |
| Participant 8 (Week 0) | 4 |
| Participant 8 (Week 12) | 3 |
| Participant 9 (Week 0) | 3 |
| Participant 9 (Week 12) | 3 |
The DPSS is a clinician-rated scale used to rate 8 domains commonly seen in patients with psychotic disorders. Each domain was rated on a 5-point scale (0 to 4) with anchored description of endpoints. Total score was computed by summing the scores of individual items (range of 0-32). Higher scores represent more severe condition. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
| units on a scale | Cohort 1 |
|---|---|
| Participant 1 (Week 0) | 12 |
| Participant 1 (Week 12) | 4 |
| Participant 2 (Week 0) | 8 |
| Participant 2 (Week 12) | 2 |
| Participant 3 (Week 0) | 8 |
| Participant 3 (Week 12) | 8 |
| Participant 4 (Week 0) | 14 |
| Participant 5 (Week 0) | 9 |
| Participant 5 (Week 12) | 4 |
| Participant 6 (Week 0) | 7 |
| Participant 6 (Week 12) | 4 |
| Participant 7 (Week 0) | 5 |
| Participant 7 (Week 12) | 8 |
| Participant 8 (Week 0) | 4 |
| Participant 8 (Week 12) | 4 |
| Participant 9 (Week 0) | 4 |
| Participant 9 (Week 12) | 6 |
AMPL of the individual participant during the active assessment phase was reported.
| nanogram per milliliter | Cohort 1 |
|---|---|
| Participant 1- ARIPIPRAZOLE | 596.00 |
| Participant 1- DEHYDROARIPIPRAZOLE | 139.00 |
| Participant 2- OLANZAPINE | 27.30 |
| Participant 2- PALIPERIDONE | 45.10 |
| Participant 3- 7-OH QUETIAPINE | 43.10 |
| Participant 3-NORQUETIAPINE | 660.00 |
| Participant 3-QUETIAPINE | 280.00 |
| Participant 3-QUETIAPINE SULFOXIDE | 660.00 |
| Participant 5-7-OH QUETIAPINE | 7.72 |
| Participant 5-NORQUETIAPINE | 153.00 |
| Participant 5-QUETIAPINE | 50.30 |
| Participant 5-QUETIAPINE SULFOXIDE | 321.00 |
| Participant 6-ARIPIPRAZOLE | 464.00 |
| Participant 6-DEHYDROARIPIPRAZOLE | 112.00 |
| Participant 7-PALIPERIDONE | 31.00 |
| Participant 7-RISPERIDONE | 26.20 |
| Participant 8-ARIPIPRAZOLE | 168.00 |
| Participant 8-DEHYDROARIPIPRAZOLE | 33.00 |
| Participant 9- 7-OH QUETIAPINE | 0.200 |
| Participant 9- NORQUETIAPINE | 2.00 |
| Participant 9- PALIPERIDONE | 0.100 |
| Participant 9- QUETIAPINE | 2.00 |
| Participant 9- QUETIAPINE SULFOXIDE | 2.00 |
| Participant 9- RISPERIDONE | 0.100 |
The CASP and data on concomitant medications and psychosocial treatments were used to evaluate the impact of AMPL results on other aspects of clinical decision making.
| participants | Cohort 1 |
|---|---|
| Side Effects Of Medication | 3 |
| Attitude Toward Treatment | 2 |
| Report of Increased Symptoms | 4 |
| Report of Decrease in Symptoms | 3 |
| Patient Still Symptomatic | 1 |
| Patient Ideation | 1 |
The CRS is an ordinal scale filled by the clinician. The scores range from 1 to 7 that were used to quantify the clinician's assessment of treatment adherence by the patient. Higher scores indicate greater adherence. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
| units on a scale | Cohort 1 |
|---|---|
| Participant 1 (Week 0) | 7 |
| Participant 1 (Week 12) | 7 |
| Participant 2 (Week 0) | 7 |
| Participant 2 (Week 12) | 7 |
| Participant 3 (Week 0) | 7 |
| Participant 3 (Week 12) | 7 |
| Participant 4 (Week 0) | 7 |
| Participant 5 (Week 0) | 7 |
| Participant 5 (Week 12) | 7 |
| Participant 6 (Week 0) | 7 |
| Participant 6 (Week 12) | 7 |
| Participant 7 (Week 0) | 7 |
| Participant 7 (Week 12) | 7 |
| Participant 8 (Week 0) | 7 |
| Participant 8 (Week 12) | 7 |
| Participant 9 (Week 0) | 7 |
| Participant 9 (Week 12) | 7 |
The BARS is a 4-item scale that includes 3 questions and an overall visual analog rating scale that assesses participant's knowledge about his/her medication. The key measure of adherence is the visual analog scale and assesses the percentage of doses taken by the participants in the past month (0 percent \[%\] - 100%). The 3 questions include: number of prescribed doses per day, number of days in the past month when the participant did not take the prescribed doses, and the number of days in the past month when the participant took less than the prescribed dose. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
| percent adherence | Cohort 1 |
|---|---|
| Participant 1 (Week 0) | 100 |
| Participant 1 (Week 12) | 100 |
| Participant 2 (Week 0) | 100 |
| Participant 2 (Week 12) | 100 |
| Participant 3 (Week 0) | 100 |
| Participant 3 (Week 12) | 100 |
| Participant 4 (Week 0) | 97 |
| Participant 5 (Week 0) | 93 |
| Participant 5 (Week 12) | 90 |
| Participant 6 (Week 0) | 90 |
| Participant 6 (Week 12) | 96 |
| Participant 7 (Week 0) | 90 |
| Participant 7 (Week 12) | 95 |
| Participant 8 (Week 0) | 100 |
| Participant 8 (Week 12) | 100 |
| Participant 9 (Week 0) | 100 |
| Participant 9 (Week 12) | 100 |
The PSS is a brief scale designed to capture a psychiatric patient's satisfaction with a clinician. The scale covers 6 domains: Trust (3 items), Communication (3 items), Exploration of Ideas/Options (2 items), Body Language (2 items), Active Listening (4 items), and Miscellaneous Items (6 items). Out of the 20 items, the first 19 are scored on a 5-point Likert Scale (1=strongly disagree, 2=disagree, 3=satisfactory, 4=agree, 5=strongly agree). The last question (6f) is a free-response question asking for input on how the clinician might improve. Sum of scores of individual items give a total score (range 9-95). Higher scores indicate greater degree of satisfaction. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
| units on a scale | Cohort 1 |
|---|---|
| Participant 1 (Week 0) | 76 |
| Participant 1 (Week 12) | 76 |
| Participant 2 (Week 0) | 52 |
| Participant 2 (Week 12) | 57 |
| Participant 3 (Week 0) | 57 |
| Participant 3 (Week 12) | 57 |
| Participant 4 (Week 0) | 48 |
| Participant 5 (Week 0) | 66 |
| Participant 5 (Week 12) | 64 |
| Participant 6 (Week 0) | 76 |
| Participant 6 (Week 12) | 76 |
| Participant 7 (Week 0) | 76 |
| Participant 7 (Week 12) | 72 |
| Participant 8 (Week 0) | 63 |
| Participant 8 (Week 12) | 72 |
| Participant 9 (Week 0) | 71 |
| Participant 9 (Week 12) | 76 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | — | 1/9 (11.1%) | 4/9 (44.4%) |
| Event | Cohort 1 |
|---|---|
| DeathGeneral disorders | 1/9 |
| Event | Cohort 1 |
|---|---|
| External ear inflammationEar and labyrinth disorders | 1/9 |
| PharyngitisInfections and infestations | 1/9 |
| AnxietyPsychiatric disorders | 1/9 |
| DepressionPsychiatric disorders | 1/9 |
| RestlessnessPsychiatric disorders | 1/9 |
| MiliariaSkin and subcutaneous tissue disorders | 1/9 |
| Age, Categorical(Participants) | Cohort 1 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 8 |
| >=65 years | 1 |
| Age, Continuous(years) | Cohort 1 |
|---|---|
| Mean | 46.2 ± 13.15 |
| Sex: Female, Male(Participants) | Cohort 1 |
|---|---|
| Female | 2 |
| Male | 7 |
The record gives a start of May 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aripiprazole · Olanzapine · Paliperidone · Quetiapine · Risperidone
Janssen Research & Development, LLC →